GOLDMAN SACHS GROUP INC - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 36 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.8%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2017$24,000
-22.6%
16,403
-14.1%
0.00%
Q1 2017$31,000
-32.6%
19,106
+50.3%
0.00%
Q4 2016$46,000
-17.9%
12,711
+14.3%
0.00%
Q1 2016$56,000
-81.6%
11,122
-55.5%
0.00%
Q2 2015$305,00025,0000.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q3 2015
NameSharesValueWeighting ↓
SV Health Investors, LLC 2,857,667$23,118,00012.93%
Clarus Ventures, LLC 2,752,488$22,268,00012.81%
Camber Capital Management LP 1,000,000$8,090,0000.69%
Rhenman & Partners Asset Management AB 300,427$2,430,0000.39%
SPHERA FUNDS MANAGEMENT LTD. 327,476$2,595,0000.33%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 628,482$5,084,0000.20%
Spark Investment Management LLC 32,500$263,0000.03%
Tower Research Capital LLC (TRC) 10,764$87,0000.01%
VANGUARD GROUP INC 4,732,472$168,937,0000.01%
Alyeska Investment Group, L.P. 40,220$325,0000.00%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders